Risk Prediction for Breast, Endometrial, and Ovarian Cancer in White Women Aged 50 y or Older: Derivation and Validation from Population-Based Cohort Studies

PLoS Medicine

Volumn 10, Issue 7, 2013, Pages

  Pfeiffer, Ruth M ^a   Park, Yikyung ^a   Kreimer, Aimée R ^a   Lacey, James V ^b   Pee, David ^c   Greenlee, Robert T ^d   Buys, Saundra S ^e   Hollenbeck, Albert ^f   Rosner, Bernard ^g   Gail, Mitchell H ^a   Hartge, Patricia ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

^d MARSHFIELD CLINIC   (United States)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^f AARP   (United States)

^g CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; TAMOXIFEN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST BIOPSY; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; DISEASE CLASSIFICATION; ENDOMETRIOSIS; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC SURGERY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MODEL; OVARY CANCER; QUESTIONNAIRE; RISK FACTOR; SMOKING; TOBACCO; UTERUS MYOMA; VALIDATION PROCESS;

EID: 84881232017     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001492     Document Type: Article

References (29)

1. Claus EB, Risch N, Thompson WD, (1993) The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 28: 115-120.
2. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, et al. (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81: 1879-1886.
3. Gail MH, Costantino JP, Pee D, Bondy M, Newman L, et al. (2007) Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 99: 1782-1792.
4. Tyrer J, Duffy SW, Cuzick J, (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23: 1111-1130.
5. Vachon CM, van Gils CH, Sellers TA, Scott CG, Maloney SD, et al. (2007) Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res 9: 217.
6. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, et al. (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91: 1541-1548.
7. Rosner BA, Colditz GA, Webb PM, Hankinson SE, (2005) Mathematical models of ovarian cancer incidence. Epidemiology 16: 508-515.
8. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al. (2011) SEER cancer statistics review, 1975-2008. Bethesda (Maryland): National Cancer Institute. Available: http://seer.cancer.gov/csr/1975_2008/. Accessed 24 June 2013.
9. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388.
10. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741.
11. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, et al. (2009) American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27: 3235-3258.
12. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, et al. (2000) Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21: 273S-309S.
13. Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, et al. (2001) Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 154: 1119-1125.
14. Michaud DS, Midthune D, Hermansen S, Leitzmann M, Harlan L, et al. (2005) Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Registry Manag 32: 70-75.
15. Colditz GA, Hankinson SE, (2005) The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 5: 388-396.
16. Fritz A, Percy C, Jack A, Shanmugaratnam A, Sobin L, et al. (2000) International classification of diseases for oncology, third edition. Geneva: World Health Organization.
17. Centers for Disease Control and Prevention National Center for Health Statistics (2013) National Health and Nutrition Examination Survey: NHANES 1999-2000. Available: http://wwwn.cdc.gov/nchs/nhanes/search/nhanes99_00.aspx. Accessed 6 July 2013.
18. Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Data. Available: http://wwwn.cdc.gov/brfss/index.htm.
19. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, et al. (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91: 1829-1846.
20. Freedman AN, Yu BB, Gail MH, Costantino JP, Graubard BI, et al. (2011) Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 29: 2327-2333.
21. Flegal KM, Carroll MD, Ogden CL, Curtin LR, (2010) Prevalence and trends in obesity among U.S. adults, 1999-2008. JAMA 303: 235-241.
22. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, et al. (2013) SEER cancer statistics review, 1975-2010: cancer of the corpus and uterus, NOS (invasive). Bethesda (Maryland): National Cancer Institute. Available: http://seer.cancer.gov/csr/1975_2010/results_merged/sect_07_corpus_uteri.pdf. Accessed 6 July 2013.
23. Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, et al. (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98: 1215-1226.
24. Barlow WE, White E, Ballard-Barbash R, Vice PM, Titus-Ernstoff L, et al. (2006) Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98: 1204-1214.
25. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, et al. (2008) Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 148: 337-347.
26. Colditz GA, Rosner B, (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 152: 950-964.
27. Petracci E, Decarli A, Schairer C, Pfeiffer RM, Pee D, et al. (2011) Risk factor modification and projections of absolute breast cancer risk. J Natl Cancer Inst 103: 1037-1048.
28. Gail MH, Pfeiffer RM, (2005) On criteria for evaluating models of absolute risk. Biostatistics 6: 227-239.
29. Wu LC, Graubard BI, Gail MH, (2012) Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years. Ann Intern Med 157: 597-598.